GRCL

Gracell Biotechnologies Inc. American Depositary Shares
GRCL

Overview Fund Trends Analyst Outlook Journalist View
Delisted

GRCL was delisted on the 21st of February, 2024.

Back to rankings
 

About: Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.

Employees: 314

Healthcare Drug Manufacturers - General
Price charts implemented using Lightweight Charts™